| Q93197932 | A patent review of the ubiquitin ligase system: 2015-2018 |
| Q35620999 | Alternative modulation of protein-protein interactions by small molecules |
| Q60923023 | An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors |
| Q49565626 | Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics |
| Q92073027 | Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs |
| Q26749008 | Chemical Variations on the p53 Reactivation Theme |
| Q51299491 | Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. |
| Q42378380 | Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer |
| Q27684203 | Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein–Protein Interaction Inhibitor |
| Q89823393 | Degradation of proteins by PROTACs and other strategies |
| Q35859325 | Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities |
| Q90162056 | Design, Synthesis, and Biological Evaluation of Aromatic Amide-Substituted Benzimidazole-Derived Chalcones. The Effect of Upregulating TP53 Protein Expression |
| Q34358585 | Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors |
| Q64239493 | Development and structural characterization of an engineered multi-copper oxidase reporter of protein-protein interactions |
| Q30670705 | Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in |
| Q33572704 | Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine [...] |
| Q90331262 | Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression |
| Q34063712 | Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction |
| Q38191796 | Drugging the p53 pathway: understanding the route to clinical efficacy |
| Q88334098 | Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia |
| Q94952548 | Emerging New Concepts of Degrader Technologies |
| Q58697064 | Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q42217007 | Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. |
| Q35871210 | How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures. |
| Q34545841 | Induced protein degradation: an emerging drug discovery paradigm |
| Q91923645 | Inhibition of p53 inhibitors: progress, challenges and perspectives |
| Q35925277 | Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds |
| Q42651903 | MDM2 Antagonists Counteract Drug-Induced DNA Damage. |
| Q91755518 | MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) |
| Q97531386 | MDM2 inhibition: an important step forward in cancer therapy |
| Q38865504 | Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. |
| Q26775356 | Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics |
| Q90024713 | Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells |
| Q38195457 | Oncogenic protein interfaces: small molecules, big challenges. |
| Q33998827 | Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition |
| Q34481459 | Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions |
| Q38872029 | Pharmacological activation of wild-type p53 in the therapy of leukemia |
| Q38286198 | Pharmacological reactivation of p53 as a strategy to treat cancer. |
| Q90322572 | Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells |
| Q36828178 | Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas |
| Q37433613 | Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. |
| Q96690650 | Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2 |
| Q38825845 | Reactivation of p53 via MDM2 inhibition |
| Q99616637 | Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials |
| Q36140846 | Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. |
| Q55386099 | Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome. |
| Q96348276 | Regulating tumor suppressor genes: post-translational modifications |
| Q38238600 | Resistance acquisition to MDM2 inhibitors. |
| Q36734163 | Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q35411745 | Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach |
| Q93166847 | Selective Inhibitors of T Cell Receptor Recognition of Antigen-MHC Complexes for Rheumatoid Arthritis |
| Q42544825 | Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions |
| Q35555133 | Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions |
| Q89629372 | Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs |
| Q98612686 | Senotherapeutic drugs for human intervertebral disc degeneration and low back pain |
| Q28548249 | Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment |
| Q91558966 | Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci |
| Q54992503 | Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets. |
| Q35617077 | Small-molecule MDM2-p53 inhibitors: recent advances |
| Q98894841 | Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives |
| Q35087851 | Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. |
| Q35738960 | State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors |
| Q39747547 | Structure- and ligand-based virtual screening identifies new scaffolds for inhibitors of the oncoprotein MDM2. |
| Q89927396 | Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents |
| Q58726403 | Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions |
| Q35687836 | Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? |
| Q38749151 | Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. |
| Q37158445 | Targeting ubiquitination for cancer therapies. |
| Q50448531 | The Evolution of Tumor Formation in Humans and Mice with Inherited Mutations in the p53 Gene. |
| Q36692848 | The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma |
| Q47096280 | The Role of MDM2 in Promoting Genome Stability versus Instability. |
| Q38637803 | The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers. |
| Q57162865 | The p53 Pathway in Glioblastoma |
| Q92799263 | The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors |
| Q90093670 | The role of ubiquitination in tumorigenesis and targeted drug discovery |
| Q40688335 | The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors |
| Q91701515 | p53 modifications: exquisite decorations of the powerful guardian |